The Ultimate Body Contour: GLP-1/GIP + EvolveX
Achieving your dream body isn’t just about losing weight—it’s about sculpting a lean, toned, and confident new you.
At iCare Medical, we have combined the medical science of GLP-1/GIP dual-receptor agonists with the advanced contouring power of EvolveX. This synergistic treatment addresses weight loss from the inside out, ensuring that as the pounds come off, your skin stays firm, tight, and beautifully toned.
1. Medical Weight Loss (GLP-1/GIP)
GLP-1/GIP receptor agonist mimics natural gut hormones to regulate your appetite, slow digestion, and improve metabolic health. It targets deep visceral fat while making healthy eating feel effortless.
Real, Steady Progress: Our average patient safely and consistently loses 3 kg per month.
Full Medical Supervision: Tailored dosages to fit your body’s unique needs
2. Advanced Skin Tightening & Toning (EvolveX)
As you lose weight, EvolveX ensure your skin shrinks with you. Utilising a combination of Bipolar Radiofrequency (RF) energy and Electrical Muscle Stimulation (EMS),
EvolveX works remodel-magic on your tissue.
Reduces Skin Laxity: The RF energy heats the deep layers of your skin, stimulating fresh collagen to tighten and firm loose skin.
Defines Muscle: EMS technology delivers deep muscle contractions to tone areas like the abdomen, glutes, and thighs.
Zero Downtime: A completely non-invasive, hands-free treatment that feels like a warm, deep-tissue massage.
Essentially, our protocol minimises the risk of loose, flabby skin as you lose weight successfully.
Latest research on GLP1/GIP receptor agonist (Mounjaro)
The provided sources outline a powerful array of health benefits associated with GLP-1 receptor agonists and dual agonists like Mounjaro (tirzepatide) and GLP-1 receptor agonists like Wegovy (semaglutide). While these medications were originally developed for blood glucose control, emerging clinical data demonstrates that their systemic effects reach far beyond glycaemic management.
Here is a summary of the key health benefits highlighted in the articles:
1. Cardiovascular Protection
● Reduced Risk of Major Cardiac Events: The medication class provides an average 14% relative risk reduction for Major Adverse Cardiovascular Events (MACE), including cardiovascular death, acute heart attacks, and strokes.
● Plaque Stabilisation: Rather than just managing risk factors, these drugs appear to directly slow the progression of atherosclerosis (plaque buildup in the arteries) and stabilise existing plaques, making them less likely to rupture and cause acute vascular blockages.
● Systemic Risk Improvement: Patients consistently see reductions in blood pressure and total cholesterol alongside their glucose management.
2. Emerging Anti-Cancer and Survival Benefits
● Lowered Risk of Cancer Development: Large-scale observational data presented at the American Society of Clinical Oncology (ASCO) indicates that these medications are linked to a lower risk of developing several malignancies, including a noted reduction in prostate cancer risk for high-risk men and up to a 35% reduction in breast cancer risk.
● Reduction in Metastasis: Users were 38% to 50% less likely to see existing cancers (such as lung, breast, colorectal, and liver cancers) progress to advanced, metastatic disease compared to patients on other classes of diabetes treatments.
● Improved Overall Survival: The data revealed a roughly one-third reduction in the risk of death (better overall survival) across six distinct tumor types— breast, prostate, colorectal, lung, liver, and kidney cancers.
● Mechanism Beyond Weight Loss: Researchers hypothesise that these benefits are driven not just by weight loss, but by the drugs' direct anti-inflammatory properties, regulation of insulin signalling, and positive interactions with the immune system (including better outcomes when paired with cancer immunotherapies).
3. Metabolic and Glycaemic Control
● Dynamic Insulin Regulation: The medication acts glucose-dependently, stimulating insulin secretion from the pancreas specifically in response to elevated blood sugar levels, making it highly effective at lowering HbA1c without a high risk of hypoglycaemia.
● Potent Weight and Visceral Fat Management: By increasing satiety and slowing gastric emptying to curb hunger, it significantly reduces body weight and waist circumference, which directly mitigates the underlying metabolic stress driving prediabetes and insulin resistance.
4. Additional Systemic Benefits
● Organ Protection: Substantial reductions in mortality and malignancy rates were specifically noted in high-risk patient subsets, such as those concurrently managing type 2 diabetes and stage 3 kidney disease.
● Broader Applications: Clinical benefits are also actively being demonstrated for sleep apnea, as well as potential applications in managing alcohol and substance abuse.
● Improvement in Fatty liver : Mounjaro (tirzepatide) significantly improves and can actively resolve non-alcoholic fatty liver disease (NAFLD) and MASH (metabolic dysfunction-associated steatohepatitis). The medication reduces liver fat through substantial weight loss, improved insulin sensitivity, and lowered inflammation. Not Currently FDA-Approved for Liver Disease: While highly effective at resolving liver fat—and often prescribed off-label for this reason.
● Reversal of pre-diabetes: Clinical Trial Success: SURMOUNT trial research indicates that more than 94% of prediabetic participants taking the medication returned to normal blood sugar levels.
